Legend Biotech Corp stock (US52490G1022): earnings momentum and analyst optimism meet rising short interest

Legend Biotech Corp shares have been volatile after strong growth in CAR-T revenues, mixed quarterly earnings and rising short interest, while Wall Street analysts still see substantial upside potential for the Nasdaq-listed biotech.

Legend Biotech Corp has drawn fresh attention from investors after reporting strong year-on-year revenue growth, while the stock pulled back sharply in recent sessions and short interest climbed, even as Wall Street analysts continue to project significant upside for the Nasdaq-listed CAR-T specialist, according to data from MarketBeat as of 05/15/2026 and recent industry coverage from Xtalks as of 05/08/2026.MarketBeat as of 05/15/2026Xtalks as of 05/08/2026

As of: 16.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: LEGN
• Sector/industry: Biotechnology, oncology therapies
• Headquarters/country: Somerset, New Jersey, United States
• Core markets: Oncology treatments in the US, Europe and selected global regions
• Key revenue drivers: CAR-T therapy Carvykti and partnered oncology programs
• Home exchange/listing venue: Nasdaq (ticker: LEGN)
• Trading currency: US dollar (USD)

Legend Biotech Corp: core business model

Legend Biotech Corp focuses on developing and commercializing cell-based immunotherapies for cancer, with a particular emphasis on chimeric antigen receptor T-cell, or CAR-T, technologies, positioning the company in a high-growth niche of the biotech industry that is attracting substantial clinical and investor interest, as underlined in its corporate materials and specialist healthcare coverage.Legend Biotech website as of 05/10/2026

The centerpiece of the business model today is Carvykti, a BCMA-directed CAR-T therapy for multiple myeloma that Legend co-develops and commercializes globally with Johnson & Johnson, giving the company access to large-scale commercial infrastructure while retaining meaningful economic participation in one of the fastest-growing segments of oncology, according to Xtalks as of 05/08/2026.Xtalks as of 05/08/2026

Beyond Carvykti, Legend Biotech Corp invests heavily in a pipeline of next-generation cell therapies targeting hematologic malignancies and solid tumors, aiming to leverage its platform, manufacturing know-how and regulatory experience to launch additional products over time, which could further diversify revenue away from reliance on a single flagship therapy if clinical and regulatory milestones are achieved, based on information from the company and sector reports.Legend pipeline overview as of 04/30/2026

The company’s partnership-centric model, highlighted by its alliance with Johnson & Johnson, reduces some of the commercial risk associated with launching complex biologic therapies, while still exposing shareholders to the volatility inherent in clinical development, manufacturing scale-up and reimbursement decisions across major healthcare markets, factors that often drive swings in biotech valuations on US exchanges.

Main revenue and product drivers for Legend Biotech Corp

A key recent development for Legend Biotech Corp was the disclosure that Carvykti net trade sales were estimated at around 597 million US dollars for the first quarter of 2026, underscoring the therapy’s rapid adoption and supporting the company’s status as one of the fastest-growing biotech names in the Americas, according to Xtalks as of 05/08/2026.Xtalks as of 05/08/2026

In its most recently reported quarter, Legend Biotech Corp posted a revenue growth rate of 56.5 percent year over year, reflecting the scaling of Carvykti-related income and milestone payments, although the company remained loss-making on a per-share basis, reporting a quarterly loss of 0.03 dollars per share versus a consensus expectation of a 0.02 dollar loss, according to MarketBeat as of 05/15/2026.MarketBeat as of 05/15/2026

The divergence between robust top-line growth and ongoing net losses illustrates the typical pattern for commercial-stage biotech firms that continue to invest in research and development, manufacturing capacity and post-approval trials, and for Legend Biotech Corp these expenditures are intended to sustain its competitive position in CAR-T and adjacent cell-therapy modalities amid intensifying competition from both large pharmaceutical companies and specialized biotech peers in the US and abroad.

For the broader business, revenue visibility is closely linked to Carvykti demand in multiple myeloma, reimbursement frameworks in key markets, and the timing of potential label expansions to earlier lines of therapy, which could significantly expand the addressable patient population but would require successful clinical data and regulatory review, factors that investors in Legend Biotech Corp commonly monitor via earnings releases and medical conference presentations reported by financial and healthcare media.

Share price performance, volatility and short interest

Legend Biotech Corp shares have seen notable volatility in recent trading, with the stock closing at 27.55 US dollars on May 15, 2026, down 3.67 percent on the day on Nasdaq, and extending losses to 27.13 dollars in extended trading, according to MarketBeat as of 05/15/2026.MarketBeat as of 05/15/2026

Despite this pullback, Legend Biotech Corp shares have still advanced from 21.74 dollars at the start of 2026, marking a year-to-date gain of around 26.7 percent through May 15, 2026, highlighting how quickly sentiment can shift in the biotech sector as investors react to earnings details, competitive updates and risk appetite across growth-oriented healthcare stocks, according to MarketBeat as of 05/15/2026.MarketBeat as of 05/15/2026

Short interest has also become a notable datapoint: as of April 30, 2026, approximately 17.0 million Legend Biotech Corp shares were sold short, representing about 9.19 percent of the public float and marking an 11.55 percent decline compared with the prior reading, based on MarketBeat short-interest statistics published on 05/10/2026.MarketBeat short interest as of 05/10/2026

A short-interest level at high single digits of float indicates that a subset of market participants is positioning for potential downside or hedging exposure, yet the recent reduction in short interest suggests that some bearish investors have started to cover positions, a dynamic that can add to price swings if sentiment turns abruptly following clinical updates, regulatory news or changes in macroeconomic conditions affecting risk assets.

Liquidity remains relatively robust for a mid-cap biotech name, with recent daily trading volumes reported by MarketBeat around 1.8 million shares compared with an average volume of 2.96 million shares as of mid-May 2026, providing US-based investors with the ability to adjust positions without severely impacting the price under normal market conditions, though sharp moves can still occur around news releases.MarketBeat as of 05/15/2026

Analyst sentiment and valuation context

On Wall Street, Legend Biotech Corp is currently viewed favorably by covering analysts, with MarketBeat reporting a consensus rating of "Moderate Buy" based on 11 buy ratings, 3 hold ratings and 1 sell rating, and a consensus price target of 59.00 US dollars as of 05/15/2026, implying more than 100 percent upside from the latest closing price of 27.55 dollars, although actual outcomes may differ materially from projections.MarketBeat as of 05/15/2026

Complementing this view, a May 2026 article on TipRanks highlighted Legend Biotech Corp as one of three healthcare stocks favored by analysts, noting a "Strong Buy" consensus based on 10 buy ratings and one hold over the prior three months and citing an average price target of about 55.90 dollars, which also signaled significant potential upside versus contemporaneous trading levels, according to TipRanks as of 05/07/2026.TipRanks as of 05/07/2026

There have also been incremental adjustments to individual price targets, such as a recent move by Morgan Stanley to trim its Legend Biotech Corp target from 49 to 48 US dollars while maintaining a positive stance, which illustrates how analysts refine their models as new clinical, competitive and financial information emerges, based on a report cited by The Fly and summarized on TipRanks as of late April 2026.TipRanks as of 04/28/2026

For valuation, MarketBeat lists a market capitalization of approximately 5.10 billion US dollars as of May 15, 2026, and no meaningful price-to-earnings ratio due to Legend Biotech Corp’s negative earnings, meaning that investors often compare the stock on metrics such as revenue growth, potential peak sales for Carvykti and pipeline assets, and strategic positioning within the broader oncology landscape.MarketBeat as of 05/15/2026

Sector comparison data from Investing.com show that Legend Biotech Corp’s recent performance has lagged certain high-flying biotech benchmarks over a multi-year period but has roughly tracked the S&P 500’s gains, underscoring the stock’s blend of high-growth potential and event-driven risk, based on Investing.com competitor analysis as of 05/12/2026.Investing.com as of 05/12/2026

Why Legend Biotech Corp matters for US investors

For US-based investors, Legend Biotech Corp represents an opportunity to gain exposure to the rapidly evolving CAR-T space via a company whose primary listing and trading currency are aligned with US markets, making it accessible through standard brokerage accounts and included in many healthcare and biotechnology indices that underpin exchange-traded funds.

The company’s collaboration with Johnson & Johnson provides a link between early-stage biotech innovation and large-pharma commercialization capabilities, a model that has been central to many value-creation stories in the US biotechnology sector, where smaller firms rely on strategic alliances to navigate the complex path from clinical development to global market access, as discussed in various sector commentaries and company disclosures.Legend investor relations as of 05/10/2026

At the same time, Legend Biotech Corp’s dependence on a single commercial product, exposure to regulatory and manufacturing risks, and sensitivity to sentiment around loss-making growth companies mean that the stock can experience pronounced swings that may not always correlate with broader US equity indices, an aspect that portfolio managers and individual traders often consider when managing risk and diversification.

Conclusion

Legend Biotech Corp stands at an important juncture where strong revenue growth from Carvykti and supportive analyst sentiment coexist with lingering losses, rising though recently moderating short interest, and notable share-price volatility on Nasdaq, leaving the stock sensitive to upcoming clinical, regulatory and commercial updates that could influence market expectations in either direction.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.